share_log

bluebird bio | 10-Q: Q2 2024 Earnings Report

bluebird bio | 10-Q: Q2 2024 Earnings Report

bluebird bio | 10-Q：2024财年二季报
美股SEC公告 ·  2024/09/27 13:24

Moomoo AI 已提取核心信息

bluebird bio reported Q2 2024 revenue of $16.1 million, up from $6.9 million in Q2 2023, driven by increased sales of its gene therapy products ZYNTEGLO, SKYSONA and LYFGENIA. However, the company posted a net loss of $81.4 million compared to a $62.8 million loss in the prior year period, as cost of product revenue increased to $28.9 million and operating expenses rose to $75.5 million.The company faces significant financial challenges, with management expressing substantial doubt about its ability to continue as a going concern. Based on current forecasts, existing cash and cash equivalents of $144.1 million are expected to fund operations only into Q1 2025. In March 2024, bluebird secured a term loan facility of up to $175 million from Hercules Capital to extend its runway.To optimize costs, bluebird announced a restructuring in September 2024 that will reduce workforce by 25%. The company continues to focus on commercial execution of its three FDA-approved gene therapies while managing manufacturing challenges and seeking adequate pricing and reimbursement. Management is exploring additional financing options and implementing cost-saving initiatives to sustain operations.
bluebird bio reported Q2 2024 revenue of $16.1 million, up from $6.9 million in Q2 2023, driven by increased sales of its gene therapy products ZYNTEGLO, SKYSONA and LYFGENIA. However, the company posted a net loss of $81.4 million compared to a $62.8 million loss in the prior year period, as cost of product revenue increased to $28.9 million and operating expenses rose to $75.5 million.The company faces significant financial challenges, with management expressing substantial doubt about its ability to continue as a going concern. Based on current forecasts, existing cash and cash equivalents of $144.1 million are expected to fund operations only into Q1 2025. In March 2024, bluebird secured a term loan facility of up to $175 million from Hercules Capital to extend its runway.To optimize costs, bluebird announced a restructuring in September 2024 that will reduce workforce by 25%. The company continues to focus on commercial execution of its three FDA-approved gene therapies while managing manufacturing challenges and seeking adequate pricing and reimbursement. Management is exploring additional financing options and implementing cost-saving initiatives to sustain operations.
bluebird bio报告2024年第二季度营业收入为1610万美元，较2023年第二季度的690万美元增长，这得益于其基因治疗产品ZYNTEGLO、SKYSONA和LYFGENIA销售的增加。然而，公司净亏损为8140万美元，相比于去年同期的6280万美元亏损，产品收入成本增加至2890万美元，营业费用上升至7550万美元。公司面临重大财务挑战，管理层对其作为持续经营的能力表示了实质性怀疑。根据当前的预测，现有的现金及现金等价物为14410万美元，预计仅能支持运营至2025年第一季度。2024年3月，bluebird从海格投资处获得了高达17500万美元的定期贷款，以延长其资金链。为了优化成本，bluebird于2024年9月宣布进行重组，将减少25%的员工。公司继续专注于其三种获得FDA批准的基因疗法的商业执行，同时管理制造挑战，并寻求适当的定价和报销。管理层正在探索额外的融资选择，并实施节省成本的举措以维持运营。
bluebird bio报告2024年第二季度营业收入为1610万美元，较2023年第二季度的690万美元增长，这得益于其基因治疗产品ZYNTEGLO、SKYSONA和LYFGENIA销售的增加。然而，公司净亏损为8140万美元，相比于去年同期的6280万美元亏损，产品收入成本增加至2890万美元，营业费用上升至7550万美元。公司面临重大财务挑战，管理层对其作为持续经营的能力表示了实质性怀疑。根据当前的预测，现有的现金及现金等价物为14410万美元，预计仅能支持运营至2025年第一季度。2024年3月，bluebird从海格投资处获得了高达17500万美元的定期贷款，以延长其资金链。为了优化成本，bluebird于2024年9月宣布进行重组，将减少25%的员工。公司继续专注于其三种获得FDA批准的基因疗法的商业执行，同时管理制造挑战，并寻求适当的定价和报销。管理层正在探索额外的融资选择，并实施节省成本的举措以维持运营。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    Portage Biotech
    PRTG
    -- 9.600
    莱斯康制药
    LXRX
    -- 0.571
    DBV Technologies
    DBVT
    -- 6.200
    NeOnc Technologies
    NTHI
    -- 16.550
    Alumis
    ALMS
    -- 5.640
    解锁完整榜单
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。
    热门讨论
    中概股财报季火热：惊喜盈利能否延续涨势？
    1. 哪些行业可能成为本轮中概股财报季的市场焦点？ 2. 在政府强调科技创新和可持续发展的背景下，你认为哪些行业具有最大的增长潜力？ 展开
    中国两会：会议前后股票价格走势的主要要点